Media and Communications

News

2011 News Releases

Thursday, December 22, 2011
Dr. Rob Koremans to succeed Dr. Gerard van Odijk as President and CEO of Teva Europe

JERUSALEM--(BUSINESS WIRE)--Dec. 22, 2011-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that Dr. Rob Koremans, has been appointed President and CEO, Teva Europe and will join the company in March 2012. Dr. Koremans joins Teva after serving as CEO for Zentiva and most recently Senior Vice President Generic Strategy and Development at Sanofi-Aventis. After six intensive years, Dr. Gerard van Odijk, Teva Europe’s current President and CEO has decided to step down. In the next few months, Dr. Koremans and Dr. van Odijk will work closely together to ensure a smooth transi Read More »

Wednesday, December 21, 2011
Teva Announces $3 billion Share Repurchase Program

JERUSALEM--(BUSINESS WIRE)--Dec. 21, 2011-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that its Board of Directors has authorized the Company to repurchase (including through one or more subsidiaries) up to an aggregate of $3 billion of its ordinary shares/ADRs from time to time, based on market conditions. At Teva’s current market capitalization, this amount would represent approximately 8 percent of the outstanding common stock. "This share repurchase program reflects our confidence in the future outlook of our business and the company's long-term value," Read More »

Wednesday, December 21, 2011
Teva Provides 2012 Non-GAAP Financial Outlook; 2012 Non-GAAP Diluted EPS of $5.48 to $5.68

JERUSALEM--(BUSINESS WIRE)--Dec. 21, 2011-- On its conference call today, Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) provided its current outlook for non-GAAP financial performance for the full year ending December 31, 2012. This outlook is summarized below. Total net sales of approximately $22 billion, consisting of total U.S. net sales of $11 billion, total European net sales of $6.6 billion, and total ROW net sales of $4.4 billion. These figures include the following major business lines: Generic product (including API) net sales of approximately $11.8 billion, consisting of Read More »

Tuesday, December 13, 2011
Teva to Host 2012 Business Outlook Conference Call

JERUSALEM--(BUSINESS WIRE)--Dec. 13, 2011-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it will host a conference call and live webcast on Wednesday, December 21, 2011 at 8:30 a.m. ET to communicate its 2012 business outlook. A Question & Answer session will follow. In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States and Canada 866-770-7120; International 1-617-213-8065 and enter passcode 23520783. A live webcast Read More »

Monday, December 05, 2011
Teva to Present at the NASDAQ OMX 27th Investor Program

JERUSALEM--(BUSINESS WIRE)--Dec. 5, 2011-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the NASDAQ OMX 27th Investor Program with Eyal Desheh, Chief Financial Officer, Teva Pharmaceutical Industries Ltd., presenting on Tuesday, December 6, 2011 in London. What:   Teva Presentation at the NASDAQ OMX 27th Investor Program Read More »

Thursday, December 01, 2011
Teva Announces Tentative Approval of Generic Lipitor®

JERUSALEM, Dec 01, 2011 (BUSINESS WIRE) - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Atorvastatin Calcium Tablets, the generic version of Pfizer's Lipitor®. Annual sales of Lipitor® were approximately $7.8 billion in the United States as of September 2011, based on IMS sales data. Teva anticipates launching this product at the end of Ranbaxy's 180-day exclusivity period in May 2012. A Read More »

Thursday, December 01, 2011
Teva Announces Tentative Approval of Generic Lipitor®

JERUSALEM, Dec 01, 2011 (BUSINESS WIRE) - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Atorvastatin Calcium Tablets, the generic version of Pfizer's Lipitor®. Annual sales of Lipitor® were approximately $7.8 billion in the United States as of September 2011, based on IMS sales data. Teva anticipates launching this product at the end of Ranbaxy's 180-day exclusivity period in May 2012. A portion of the profits from Ranbaxy's sales of Ato Read More »

Wednesday, November 30, 2011
Teva Announces Agreement with Ranbaxy Regarding Generic Lipitor(R)

JERUSALEM, Nov 30, 2011 (BUSINESS WIRE) - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that pursuant to an agreement between its subsidiary, Teva Pharmaceuticals USA, Inc. and Ranbaxy Laboratories Limited ("Ranbaxy"), a portion of the profits from Ranbaxy's sales of Atorvastatin Calcium Tablets during Ranbaxy's 180-day first-to-file exclusivity period, will be paid to Teva. Terms of the agreement will not be disclosed.   Atorvastatin Calcium Tablets are the generic version of Pfizer's Lipitor(R) Tablets. Annual sales of Lipitor(R) were approximately $7.8 bill Read More »

Monday, November 28, 2011
Teva to Present at the 23rd Annual Piper Jaffray Health Care Conference

Jerusalem, Israel, November 28, 2011 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the 23rd Annual Piper Jaffray Health Care Conference with William Marth, President & CEO, Teva Pharmaceuticals - Americas, presenting on Wednesday, November 30, 2011 in New York. What: Teva Presentation at the 23rd Annual Piper Jaffray Health Care Conference Who: William Marth, President & CEO, Teva Pharmaceuticals - Americas When: Wednesday, November 30, 2011 at 1:30 pm EST Where: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker Read More »

Tuesday, November 22, 2011
​Teva, its Board of Directors, management and employees, mourn the passing of Eli Hurvitz.

Teva, its Board of Directors, management and employees, mourn the passing of Eli Hurvitz.   Eli Hurvitz led Teva as CEO from 1976-2002 and as Chairman of the Board from 2002-2010. Under his leadership and with his rare ability to nourish a culture of excellence and lay a long term strategic vision, Teva became the leading company in Israel economy and the biggest generic company in the world.   Eli served in a variety of public and business positions that earned him worldwide admiration and recognition.   " Today, we mourn the loss of a true pioneer, whose vision of providing acce Read More »

​​​